key: cord-0787475-287mqt6a
authors: Huynh, A.; Arnold, D. M.; Kelton, J. G.; Smith, J. W.; Moore, J. C.; Chetty, V. T.; Stacey, H. D.; Ang, J. C.; Chagla, Z.; Harvey, B. J.; Bowdish, D. M.; Miller, M. S.; Nazy, I.
title: Development of a serological assay to identify SARS-CoV-2 antibodies in COVID-19 patients
date: 2020-09-13
journal: nan
DOI: 10.1101/2020.09.11.20192690
sha: 02080dade5e2cf8dcb42834df24269e209cbf402
doc_id: 787475
cord_uid: 287mqt6a

Coronavirus Disease 2019 (COVID-19) is a global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While molecular assays are used to detect viral genetic material for the diagnosis of acute infection, reliable serological assays are needed to measure immunity against SARS-CoV-2. In this report, we describe an enzyme-linked immunosorbent assay (ELISA) that detects antibodies against the following SARS-CoV-2 recombinant proteins: the full-length spike (S) protein and the receptor-binding domain (RBD). Our assay is sensitive and specific for immunoglobulin (Ig) G, IgA and IgM anti-S protein and anti-RBD antibodies. Samples were pre-treated with Triton X-100 to inactivate potential virus without affecting antibody detection. Our in-house ELISA performed as well as the commercial EUROIMMUN and Ortho assays for anti-SARS-CoV-2 antibodies. This method provides a high-throughput assay that does not require specialized instrumentation and can be widely used to determine immunity and the dynamic range of antibodies found within SARS-CoV-2.

testing for SARS-CoV-2, followed by appropriate preventive measures, is paramount in the health care setting to prevent both nosocomial and community transmission. Currently, there is a need for tests that are capable of detecting the presence of SARS-CoV-2 specific antibodies with high accuracy to determine seroprevalence [18] . Although serology cannot distinguish between acute and chronic infection, it can identify individuals who have developed an immune response, aid in contact tracing, help identify suitable convalescent plasma donors, and can be used to evaluate vaccines.

The presence of antibodies to SARS-CoV-2 indicates the potential of protective immunity [19] . The target antigen of the antibody response to SARS-CoV-2 is a large glycoprotein termed spike (S) protein, which consists of the S1 and S2 domains. The S1 domain contains the receptor-binding domain (RBD), which is the target of most neutralizing antibodies [20] [21] [22] [23] . The SARS-CoV-2 S protein is a homotrimer essential for mediating binding to host cells through interactions with the human receptor angiotensin converting enzyme 2 (ACE2) [20] [21] [22] . Binding of the RBD to the host ACE2 receptor triggers a conformational change in the S protein that subsequently initiates membrane fusion events with the host cell [24] . Although antibodies may be generated against multiple domains within the S protein, most neutralizing antibodies bind to the RBD [23, 25] .

Antibody kinetics studies have reported that virus-specific IgG levels are lower in people who are asymptomatic or had a mild infection compared with people who had more severe symptoms and acute illness [26] . In this report, we describe a high-throughput ELISA assay with a high sensitivity and specificity for anti-SARS-CoV2 antibodies.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint

Serum samples were collected from convalescent patients who had been confirmed to be symptomatic COVID-19 infection by RT-PCR (n=10, COVID-19-positive), COVID-19-negative individuals who tested negative by RT-PCR during the pandemic (n=4) and controls collected before November 2019 (pre-COVID controls, n=332). This study was approved by the Hamilton Integrated Research Ethics Board (HIREB) and informed written consent was obtained from all participants.

A detailed protocol outlining protein production can be found in a study by Stadlbauer et al [27] .

Plasmids encoding mammalian cell codon optimized sequences for SARS-CoV-2 full-length S protein and the RBD were generously gifted from the lab of Dr. Florian Krammer (Ichan School of Medicine at Mount Sinai, NY, NY, USA). In brief, proteins were produced in Expi293 cells (ThermoFisher, Waltham, MA, USA) using the manufacturer's instructions. Post-transfection, when culture viability dropped to 40%, supernatants were collected and centrifuged at 500 x g for 5 minutes to remove cell debris. The supernatant was then incubated with shaking overnight at 4C with 1 mL of nickel-nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen, Hilden, Germany) per 25 mL of transfected cell supernatant. The following day 10 mL polypropylene gravity flow columns (Qiagen) were used to elute the protein. RBD and S proteins were concentrated in Amicon centrifugal units (Millipore, Burlington, MA, USA), 10 kDa and 50 kDa . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint respectively, prior to being resuspended in phosphate buffered saline (PBS). The purified proteins were analyzed via SDS-PAGE.

384 well plates (Nunc Maxisorp, Rochester, NY, USA) were coated overnight at 4ºC with 25 L/well of RBD (2 g/mL) or S protein (5 g/mL) suspended in 50 mM carbonate-bicarbonate buffer (pH 9.6). The plates were then blocked with 100 µL/well of 3% skim milk prepared in PBS with 0.05% Tween 20 at room temperature for 2 hours. The blocking solution was removed, and diluted patient serum samples (1/100 prepared in 1% skim milk in PBS/0.05% Tween 20) was added to the plates for 1 hour at room temperature. The plates were washed twice with PBS/0.05% Tween 20 and thrice with PBS. Bound human antibodies (IgG, IgA, or IgM) were detected with alkaline phosphatase conjugated goat anti-human IgG (-chain-specific, 1/2000, Jackson ImmunoResearch Laboratories, Inc, Westgrove, PA, USA), goat anti-human IgA (chain-specific; 1/500, Jackson ImmunoResearch Laboratories, Inc, Westgrove, PA, USA) antibody, or goat anti-human IgM (-chain-specific; 1/1000, Jackson ImmunoResearch Laboratories, Inc, Westgrove, PA, USA) antibody prepared in PBS/0.05% Tween 20. Plates were washed as before and followed with the addition of 50 µL substrate (4-nitrophenylphosphate disodium salt hexahydrate in diethanolamine; MilliporeSigma, St. Louis, MO, USA). The optical density at 405 nm and 490 nm (as a reference) was measured using a BioTek 800TS microplate reader (BioTek, Winooski, VT, USA). The cut-off was determined as the mean plus 2 standard deviations (SD) of the pre-COVID-19 control population. The specificities for each antigen/antibody combination were determined using the pre-COVID controls (n=332).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint

To determine inter-assay reproducibility, pre-COVID-19 controls (n=4) and COVID-19 positive (n=4) patient serum samples were tested in at least four separate assays using the SARS-CoV-2 ELISA described above. Results were reported as an optical density (405 nm with reference 490 nm) for each antigen and antibody isotype (IgG, IgA and IgM). Values are represented as a ratio of observed optical density to the determined assay cut-off optical density. Values above 1 ratio is considered positive in the SARS-CoV-2 ELISA.

Patient serum was inactivated to eliminate residual virus in serum samples. A subset of recovered COVID-19 positive (n=10) and pre-COVID-19 controls (n=5) were used to compare two viral inactivation methods in human sera: heat-treatment and treatment with the detergent Triton X-100 [28] [29] [30] . For heat-treatment, patient sera (0.5 mL) were incubated with rotational shaking at 56°C for 30 minutes and centrifuged for 10 minutes at 14,000 x g, after which the supernatant was collected [29] . In parallel, duplicate samples were mixed with Triton X-100 to a final concentration of 1% (v/v) [30] . The non-treated and treated patient samples were tested in the SARS-CoV-2 ELISA as previously described. We however did not test whether any virus was actually present in serum samples and whether the inactivation method was effective against virus.

To confirm the specificity of antibodies detected by the ELISA, we inhibited the binding of selected serum samples with excess fluid-phase RBD. One antibody-positive pre-COVID-19

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint control and COVID-19 positive (n=10) patient serum samples were tested in the SARS-CoV-2 ELISA described above. Samples diluted to a working concentration (1/100) were incubated with 10 times molar excess of RBD or the equivalent volume of PBS for 1 hour at room temperature before testing for antibodies in the standard assay as described.

Comparing the in-house SARS-CoV-2 ELISA to commercially available assays A subset of COVID-19 positive patient samples (n=9) and COVID-19 negative patient samples (n=5) was tested in the commercially available EUROIMMUN Anti-SARS-CoV-2 ELISA that measures anti-S1 IgG and IgA and the results were compared to our in-house assay. The same set of COVID-19 positive and pre-COVID-19 controls was also tested by the Hamilton Regional

Antibody Test that measures anti-S protein IgG for comparison.

Descriptive statistics were used to summarize the IgG, IgA, and IgM binding to S protein and RBD as measured by mean optical density across antigen replicates. Binomial 95% confidence intervals (CI) were calculated for all specificity determination. All statistical analyses were conducted using GraphPad Prism (version 7.0a, GraphPad Software, San Diego, USA).

The pre-COVID-19 control population was made up of healthy individuals (n=26) and patients suspected of immune thrombocytopenia (ITP) or heparin induced thrombocytopenia (HIT)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint (n=306) with ages ranging between 21 and 79 years at time of collection. COVID-19 positive patient samples were collected between 23-and 89-days post-symptoms. COVID-19 negative patient samples were collected between 24-and 162-days post-symptoms.

We used a set of pre-COVID-19 controls and recovered COVID-19 positive patient samples to establish an ELISA with full-length S protein and RBD. The pre-COVID-19 controls (n=332) were used to establish the background reactivity to the S protein and RBD for IgG, IgA, and IgM antibodies, separately. The COVID-19 positive patients (n=14) were used to determine the reactivity of the ELISA to the full-length S protein and RBD. Antigen concentration of S protein and RBD and serum dilutions were optimized by testing COVID-19-positive and pre-COVD19 samples. We found that RBD at 2 g/mL ( Figure 1A ) and S protein at 5 g/mL ( Figure 1B ) were the optimal concentrations since these concentrations yielded the greatest separation between OD values of COVID-19 positive and pre-COVID-19 controls results ( Figure 1 ). Saturation occurred at higher concentrations of each antigen. Using the same set of pre-COVID-19 controls and COVID-19 positive serum samples, we determined that 1/100 was the optimal serum dilution in 1% skim milk as it provided the best separation between negative and positive results (data not shown).

All recovered COVID-19 positive serum samples reacted strongly to both full-length S protein and RBD while reactivity of the pre-COVID-19 controls yielded lower levels of reactivity in most cases (below mean OD + 2SD cut-off). Reactivity of COVID-19 positive serum samples was stronger against the full-length S protein than against RBD.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint

We used pre-COVID-19 controls (n=332) to determine the background reactivity and establish assay specificity to the S protein and RBD using samples from individuals drawn before the beginning of the pandemic. The cut-off was determined as the mean + 2SD of the OD readings in the pre-COVID-19 control population. We tested these samples using the optimized SARS-CoV-2 protocol. We found that most pre-COVID-19 controls had only background reactivity for both the full-length S protein and RBD (specificity for IgG = 96.7% and 97.0%, respectively). Each antigen and antibody isotype had a few pre-COVID-19 controls that tested positive for the antibodies based on the determined cut-off. We found that specificity was the lowest for IgM against both S protein and RBD, 94.6% (18 testing positive) and 95.5% (15 testing positive) respectively. S protein-and RBD-specific IgA had the highest measured specificity, 97.3% (9 testing positive) and 97.6% (8 testing positive), respectively ( Figure 2 ).

A subset of COVID-19 positive patient samples (n=4) and pre-COVID-19 controls (n=4) were tested at least 4 times independently to determine reproducibility of the optimized SARS-CoV-2 ELISA. Upon repeat testing, we found that there was minimal inter-assay variability with repeat testing in anti-RBD IgG on average, results deviated by 4.863.53% in COVID-19 positive and 7.143.03% in pre-COVID-19 controls (Figure 4 ). This trend was similar for anti-RBD IgA . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint positive; 12.834.17% pre-COVID-19 controls), and IgM (6.082.68% COVID-19 positive;

12.374.18% pre-COVID-19 controls). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint the measured pre-COVID-19 controls became higher than the assay cut-off value after heatinactivation or treatment with Triton X-100.

To ensure the detectability of antibody binding in the sera is specific to the antigen and not non- (Table 2) for IgG antibodies to the S protein. In one COVID-negative patient sample, the inhouse assay detected weak IgG anti-RBD antibodies only, and no other reactivity, which correlated with the Ortho test. The EUROIMMUN assay detected SARS-CoV-2 antibodies in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint two COVID-19 positive patient samples where the in-house ELISA and Ortho assay did not, one of which was borderline positive for IgG anti-S1.

COVID-19 can be a severe infectious disease, however, many patients will have few or no symptoms [31] . Molecular assays to detect the viral genetic material are available for the diagnosis of acute infection, there is a need for accurate serological assays suitable to specifically detect SARS-CoV-2 antibodies [11, 12] . In this study, we describe a high throughput, reproducible, semi-quantitative serological method to detect antibodies against SARS-CoV-2.

This assay measures IgG, IgA and IgM antibody-reactivity to the immunogenic S protein and the RBD of the virus. Early serological assessments have revealed some details concerning the antibody responses to COVID-19. Following exposure, patients have an increase in IgG, IgA and IgM with peak IgA and IgM levels at 7-20 days post-infection, followed by IgG [19, 32] . Therefore, by measuring IgG, IgA, and IgM isotypes, we are capturing antibodies elicited at all stages of the immune response and are less likely to encounter false negatives. Furthermore, our in-house ELISA is simple, rapid, does not require specialized instrumentation and can be performed in standard diagnostic laboratories. Reproducibility is one of the factors to consider when establishing an assay. Using a subset of patient samples, we show that after 4 repeated measurements, there is minimal inter-assay variability.

Current COVID-19 antibody tests have shown significant variability [33] [34] [35] . Specificity is affected by various factors, including the type of test and the antigen(s). Our assay used the full-length S protein and RBD; however, some groups have tested for antibodies against the nucleocapsid protein of SARS-CoV-2 as well as testing different antibody isotypes (Ortho and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint EUROIMMUN assays) [36, 37] . Cross-reactivity of antibodies with multiple coronaviruses is an important consideration in developing the SARS-CoV-2 ELISA [38] . Similar to our results, commercial kits of SARS-CoV-2 ELISAs have identified cross-reactivity to presumably seasonal coronaviruses with IgA antibodies having a lower specificity than tests for IgG antibodies [33, 39, 40] . This may affect test specificity as individuals previously infected with seasonal coronaviruses can appear as positives in certain COVID-19 serological tests [41, 42] . In addition, other host factors, including rheumatoid factor and heterophile antibodies, can potentially crossreact and generate false-positive SARS-CoV-2 serology results [43, 44] . These factors may explain why we found 19 pre-COVID-19 controls who tested positive in the SARS-CoV-2 antibody tests. The pre-COVID-19 controls that had anti-RBD antibody were not false positive per se because antibody binding could be inhibited by excess RBD. The most likely explanation for this is that these are cross-reactive antibodies generated to seasonal coronaviruses.

Test specificity is also dependent on the assay cut-off based on the control population tested. We used a biobank containing pre-COVID-19 controls (n=332) and have used these to determine the cut-off of the SARS-CoV-2 ELISA to identify individuals with IgG, IgA and IgM antibodies against RBD or S protein. The optimized ELISA described has a specificity of greater than 94% depending on the antigen and antibody class measured (Table 1 ). Since our pre-COVID-19 controls include healthy individuals (n=26) and patients suspected of ITP or HIT (n=306), the specificity may not be representative of the general population, but include important hospitalized and elderly patients, potentially exposed to other seasonal coronaviruses.

In addition, our in-house ELISA is also in agreement with two commercial assays that report sensitivity and specificity to be 100% and 90%, respectively; however, in some studies testing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint different populations, sensitivity and specificity of the commercial assays can be as low as 65% and 73.8%, respectively [45, 46] .

To date, there have been a number of methods used for virus inactivation. However, how these inactivation methods affect the sensitivity of serological assays is unknown. To reduce risk of exposure to the virus during testing, viral inactivation is recommended before sample handling. We found that with heat-inactivation, detection of serum IgG and IgM was diminished, similar to previous studies [47] . In contrast, Triton X-100 had minimal effect on the antibody reactivity, suggesting that Triton X-100 would be a superior method for virus inactivation as it does not reduce antibody binding in IgM. The decrease in antibody levels may be related to the structural change with denaturation and aggregation when samples are heated [48, 49] . Previous studies have shown that antibodies can lose their antigen binding ability after heating, and IgM is less thermally stable than IgG due to the structure of its heavy chains [50] . Our results indicate that between the two methods, using Triton X-100 for virus inactivation is less likely to affect antibody reactivity.

We describe a high throughput ELISA that detects anti-SARS-CoV-2 antibodies important for identifying COVID-19. This SARS-CoV-2 ELISA described is sensitive, specific and reproducible allowing it to be useful for the investigations of changing infection rates and longitudinal immune responses to SARS-CoV-2. It will be useful to determine antibody titer as it may play a role in determining antibody response with great accuracy and describe disease severity. This will complement RT-PCR tests and help provide evidence of recent infection. The assay could be used to identify antibody responses in patients recovering from COVID-19 disease for convalescent plasma studies and to screen health care workers to allow for selective deployment of personnel to care for different COVID-19 populations. This assay can be used to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The authors declare no competing financial interests.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint The one pre-COVID-19 control tested positive for IgG anti-RBD antibodies that was also inhibited using excess RBD.

Inhibited with 10X RBD . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 13, 2020. . https://doi.org/10.1101/2020.09.11.20192690 doi: medRxiv preprint

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Temporal dynamics in viral shedding and transmissibility of COVID-19

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. The Lancet Infectious Diseases

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

How will country-based mitigation measures influence the course of the COVID-19 epidemic?

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Spread of SARS-CoV-2 in the Icelandic Population

Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China

Interpreting Diagnostic Tests for SARS-CoV-2

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Virological assessment of hospitalized patients with COVID-2019

Genetic diversity and evolution of SARS-CoV-2

A serological assay to detect SARS-CoV-2 seroconversion in humans

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

Structural basis of receptor recognition by SARS-CoV-2

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region

Antibody responses to SARS-CoV-2 in patients with COVID-19

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products

Clinical Characteristics of Coronavirus Disease 2019 in China

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Severe Acute Respiratory Syndrome Coronavirus 2

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses

Serum IgA, IgM, and IgG responses in COVID-19

Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

Detection of serum IgM and IgG for COVID-19 diagnosis

A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays

Diagnostic performance of seven rapid

IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients

Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2

Antibody structure, instability, and formulation

Effect of Heat Treatment on the Antigen-Binding Activity of Anti-Peroxidase Immunoglobulins in Bovine Colostrum

Kinetic and Thermodynamic Parameters for Heat Denaturation of Bovine Milk IgG, IgA and IgM

We thank Erjona Kruja for technical assistance. Funding support for this work was provided by a grant